🏛️ Verified NIH Record • Updated 2026-01-15
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4 (NCT04323189)
🔵 Active, Not Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: University of Pennsylvania
🩺 Plain-English Summary (8th-Grade Level)
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
Who can join: Review the eligibility criteria below.
Location: University of Pennsylvania — Philadelphia, Pennsylvania
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Pennsylvania — Philadelphia, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Genetics Disease
- VIGOR: Virtual Genome Center for Infant Health — Mobile, Alabama
Explore by condition: All Genetics Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.